Targeted mRNA Leverage Combined Therapeutics’ tissue-specific modified mRNA platform to position as a partner for pharma companies seeking precision delivery and reduced off-target effects in oncology and infectious disease programs.

Early Stage Advantage With a small to mid-size team and early revenue, there is an opportunity to engage in collaborations, grants, or joint development agreements to accelerate product validation and de-risk shared programs.

Strategic Partnerships Propose co-development, sponsored research, or licensing discussions with larger biotech firms seeking innovative delivery platforms to bolster their infectious disease and cancer pipelines.

Cost-Effective Engagement Given modest funding and revenue levels, offer lightweight pilot projects, milestone-driven collaborations, or flexible term sheets to convert interest into formal partnerships without high up-front risk.

Digital and Brand Leverage Assist in accelerating market visibility to potential collaborators by integrating knowledge of their tech stack considerations into outreach, showcasing how the platform integrates with existing digital ecosystems for co-branded communications.